A Procitentan, A New Novel Drug to Treat Resistant Hypertension

Resistant hypertension (RH) is defined as the failure to attain a controlled blood pressure in spite of the use of a triple combination therapy comprising a renin-angiotensin system inhibitor (RAS-i), a calcium antagonist, and a diuretic.Endothelin has been identified as a potential therapeutic agent target in the treatment of resistant hypertension. In hypertension and end-organ damage, endothelin plays a key role as a vasoconstrictor, comitogenic agent, and mediator of aldosterone and catecholamine release. ET inhibitors (receptor antagonist), currently approved by FDA in 2024 for the treatment of resistant and pulmonary hypertension. Aprocitentan seem to be also very useful for both essential hypertension and RH as well and could be used in combination of other hypertension drugs to get the best blood pressure control. Aprocitentan (Tryvio) is a novel new drug that administrated orally and showed well tolerated dual ET receptor antagonist, which has been inspected in numerous scientific studies and many clinical trials that showed hopeful results for RH control. As a result, that has been approved and optimistically it will help patients and prevent further cardiovascular disease and other organs damages. This article discusses several research that studied Aprocitentan from all aspects.